

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 October 2023 (19.10.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/201362 A9

(51) International Patent Classification:

A61K 47/64 (2017.01) *C07K 25/78* (2006.01)
A61K 31/712 (2006.01) *C12N 15/113* (2010.01)
A61K 31/713 (2006.01) *A61P 3/00* (2006.01)
A61K 47/55 (2017.01)

(21) International Application Number:

PCT/US2023/065812

(22) International Filing Date:

14 April 2023 (14.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/330,797 14 April 2022 (14.04.2022) US

(71) Applicant: **ARO BIOTHERAPEUTICS COMPANY**
[US/US]; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US).

(72) Inventors: **KULKARNI, Swapnil**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **ADDIS, Russell**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **NADLER, Steven**; 601 Walnut St., Suite 740,

Philadelphia, Pennsylvania 19106 (US). **XIN, Yao**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **DRUZINA, Zhanna**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **O'NEIL, Karyn**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **KOLAKOWSKI, Robert**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US). **ANDERSON, Stephen**; 601 Walnut St., Suite 740, Philadelphia, Pennsylvania 19106 (US).

(74) Agent: **LOTFI, Sima** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: FN3 DOMAIN-SIRNA CONJUGATES WITH ENZYME REPLACEMENT THERAPY




FIG. 1

(57) Abstract: The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, in combination with enzyme replacement therapies, as well as methods of making and using the same. Further disclosed a method of treating a glycogen storage disease, comprising administration of: a composition comprising siRNA molecules and FN3 domains conjugated to the same, and an enzyme replacement therapy (ERT) used to treat the glycogen storage disease.

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

15 February 2024 (15.02.2024)

Date of publication of the revised international search report:

20 June 2024 (20.06.2024)

(15) Information about Correction:

see Notice of 20 June 2024 (20.06.2024)